| Literature DB >> 34232198 |
Sun Tang1,2, Jing Ou1, Yu-Ping Wu1, Rui Li1, Tian-Wu Chen1, Xiao-Ming Zhang1.
Abstract
ABSTRACT: Radiomics transforms the medical images into high-dimensional quantitative features and provides potential information about tumor phenotypes and heterogeneity. We conducted a retrospective analysis to explore and validate radiomics model based on contrast-enhanced computed tomography (CECT) to predict recurrence of locally advanced oesophageal squamous cell cancer (SCC) within 2 years after trimodal therapy. This study collected CECT and clinical data of consecutive 220 patients with pathology-confirmed locally advanced oesophageal SCC (154 in the training cohort and 66 in the validation cohort). Univariate statistical test and the least absolute shrinkage and selection operator method were performed to select the optimal radiomics features. Logistic regression was conducted to build radiomics model, clinical model, and combined model of both the radiomics and clinical features. Predictive performance was judged by the area under receiver operating characteristics curve (AUC), accuracy, and F1-score in the training and validation cohorts. Ten optimal radiomics features and/or 7 clinical features were selected to build radiomics model, clinical model, and the combined model. The integrated model of radiomics and clinical features was superior to radiomics model or clinical model in predicting recurrence of locally advanced oesophageal SCC within 2 years in the training (AUC: 0.879 vs 0.815 or 0.763; accuracy: 0.844 vs 0.773 or 0.740; and F1-score: 0.886 vs 0.839 or 0.815, respectively) and validation (AUC: 0.857 vs 0.720 or 0.750; accuracy: 0.788 vs 0.700 or 0.697; and F1-score: 0.851 vs 0.800 or 0.787, respectively) cohorts. The combined model of radiomics and clinical features shows better performance than the radiomics or clinical model to predict the recurrence of locally advanced oesophageal SCC within 2 years after trimodal therapy.Entities:
Mesh:
Year: 2021 PMID: 34232198 PMCID: PMC8270616 DOI: 10.1097/MD.0000000000026557
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1The flow chart for collecting patients.
Clinical features of recurrence and non-recurrence cohorts.
| Clinical features | Recurrence (n = 148) | Non-recurrence (n = 72) | ||
| Gender (%) | Male | 108 (73) | 45 (62.5) | .113 |
| Female | 40 (27) | 27 (37.5) | ||
| Age (mean ± SD) | 62.8 ± 8.0 | 63.0 ± 7.4 | .594 | |
| Tumor location | Upper | 11 (7.5) | 11 (15.3) | .169 |
| Middle | 101 (68.2) | 47 (65.3) | ||
| Lower | 36 (24.3) | 14 (19.4) | ||
| T stage (%) | T1 | 1 (0.7) | 5 (6.9) | <.001∗ |
| T2 | 35 (23.6) | 32 (44.5) | ||
| T3 | 86 (58.1) | 30 (41.7) | ||
| T4a | 26 (17.6) | 5 (6.9) | ||
| N stage (%) | N0 | 71 (48) | 59 (81.9) | <.001∗ |
| N1 | 48 (32.4) | 9 (12.5) | ||
| N2 | 23 (15.5) | 4 (5.6) | ||
| N3 | 6 (4.1) | 0 (0) | ||
| Differentiation degree (%) | Low | 65 (43.9) | 44 (61.1) | .038∗ |
| Middle | 74 (50) | 23 (32) | ||
| High | 9 (6.1) | 5 (6.9) | ||
| TNM stage (%) | IB | 15 (10.1) | 13 (18.1) | <.001∗ |
| IIA | 43 (29.1) | 42 (58.3) | ||
| IIB | 4 (2.7) | 3 (4.2) | ||
| IIIA | 6 (4.1) | 5 (6.9) | ||
| IIIB | 68 (45.9) | 8 (11.1) | ||
| IVA | 12 (8.1) | 1 (1.4) |
Numbers in parentheses are percentages; n = number, SD = standard deviation.
Statistically significant at P < .05.
Figure 2The outlines of oesophageal cancer manually drawn on contrast-enhanced CT data. CT = computed tomography.
Figure 3Stability evaluation of the extraction of CT radiomics features by intra- (A) and inter-observer and (B) intra-class correlation coefficient (ICC). CT = computed tomography.
Figure 4Feature selection using the LASSO regression. (A) Turning optimal parameter lambda (λ) using 10-fold cross-validation and minimum criterion in LASSO model. The left and right dashed lines represent the minimum criterion and the 1-SE criterion, respectively. The 1-SE criterion has been applied. (B) LASSO coefficient profiles of the 255 radiomics features. The picture shows the optimal λ value of 0.039. 10 features with non-zero coefficients have been selected. 1-SE = 1-standard error, LASSO = least absolute shrinkage and selection operator.
Selected features with descriptions.
| Feature category | Features of recurrence vs non-recurrence | |
| Texture features | GLCM | X45.4Correlation |
| X90.1Correlation | ||
| X0.1DifferenceEntropy | ||
| X135.7InformationMeasureCorr1 | ||
| X90.1InformationMeasureCorr2 | ||
| GLRLM | X0ShortRunHighGrayLevelEmpha | |
| Intensity histogram features | Intensity histogram | X0.975Quantile |
| Shape features | Shape | Volume |
| Max3DDiameter | ||
| Roundness |
GLCM = gray-level co-occurrence matrix and GLRLM = gray-level run-length matrix. GLCM features have been constructed by 4 directions (θ = 0°, 45°, 90°, and 135°) and 3 offsets (d = 1, 4, 7); and GLRLM features have been constructed by 2 directions (θ = 0° and 90°) and one offset (d = 1).
The performance of the 3 constructed models to predict recurrence within 2 years of locally advanced oesophageal squamous cell carcinoma.
| Models | Cohort | AUC | ACC | F1-score | Sen | Spe | PPV | NPV |
| Radiomics model | Training | 0.815 | 0.773 | 0.839 | 0.892 | 0.538 | 0.791 | 0.718 |
| Validation | 0.720 | 0.700 | 0.800 | 0.870 | 0.300 | 0.741 | 0.500 | |
| Clinical model | Training | 0.763 | 0.740 | 0.815 | 0.863 | 0.500 | 0.772 | 0.650 |
| Validation | 0.750 | 0.697 | 0.787 | 0.804 | 0.450 | 0.771 | 0.500 | |
| The combined model | Training | 0.879 | 0.844 | 0.886 | 0.903 | 0.725 | 0.869 | 0.787 |
| Validation | 0.857 | 0.788 | 0.851 | 0.889 | 0.710 | 0.816 | 0.706 |
ACC = accuracy, AUC = area under the receiver operating characteristic curve, NPV = negative predictive value, PPV = positive predictive value, Sen = sensitivity, Spe = specificity.
Figure 5The ROC curves show the performance of the radiomics model, the clinical model, and the combined model of radiomics and clinical features to predict recurrence of locally advanced oesophageal squamous cell carcinoma within 2 years after trimodal therapy in (A) the training and (B) validation cohorts. ROC = receiver operating characteristic.